CB Therapeutics
Biotech firm creating cannabinoids and therapeutics for mental health via fermentation.
Competitive Advantages
CB Therapeutics operates a single precision-fermentation platform that has produced more than 100 rare molecules, including cannabinoids, tryptamines, alkaloids, and peptides. Eight granted US patents cover its yeast strains, biosynthetic pathways, downstream chemistry, and enzyme and gene mining.
The company reports that an agentic AI layer feeds lab-experiment data back into pathway design, reducing the path from prototype to product from years to months, and that it reached 99.6% CBC purity in a 2021 benchmark.
Source: cbthera.com
Market Outlook
CB Therapeutics positions its molecules for mental-health, non-opioid pain, and healthy-aging markets, where demand is growing for sustainable and standardized alternatives to crop extraction and chemical synthesis.
The company points to favorable regulatory and demand signals, including expanding GLP-1 coverage, state-level kratom and ibogaine legislation, and renewed FDA interest in psychedelic and peptide therapies, as drivers for its partnership and licensing model.
Source: cbthera.com
Product Overview
CB Therapeutics designs, develops, and manufactures rare molecules through yeast-based precision fermentation. It organizes its work into four brand programs: TryptageniX for tryptamines, TryptageniX AI for data and machine learning, Aevora for animal-free healthspan ingredients, and Korvane for non-opioid pain research.
Its compound library spans phytocannabinoids, cannabinoid analogs, terpenes, tryptamines, rare alkaloids, and food-technology proteins such as casein and collagen analogs. The company supplies partners across pharmaceutical, wellness, and food-tech markets.
Source: cbthera.com